SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer is a research paper published in Translational Lung Cancer Research (2021). On theSindex it has a DataRank of 0. It has been cited 40 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: P30 CA016672
NCI NIH HHS
Grant: R50 CA243698
NCI NIH HHS
Grant: T32 CA009302
NCI NIH HHS
Grant: T32 CA009666
NCI NIH HHS
Grant: U01 CA213273
NCI NIH HHS
Grant: P50 CA070907
NCI NIH HHS
Grant: R01 CA207295
National Institutes of Health
Grant: 5R50CA243698-02
Modeling tumor heterogeneity and treatment resistance in small cell lung cancer
National Institutes of Health
Grant: 3P30CA016672-41S4
Cancer Center Support (CORE) Grant
National Institutes of Health
Grant: 5T32CA009666-08
TRAINING FOR ACADEMIC ONCOLOGY
National Institutes of Health
Grant: 3P50CA070907-02S1
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCER
National Institutes of Health
Grant: 5R01CA207295-09
DNA damaging therapy and immune response in small cell lung cancer subtypes
National Institutes of Health
Grant: 5U01CA213273-02
Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC
FWCI
2.44
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals